QALSODY Drug Patent Profile
✉ Email this page to a colleague
When do Qalsody patents expire, and when can generic versions of Qalsody launch?
Qalsody is a drug marketed by Biogen Ma and is included in one NDA. There are three patents protecting this drug.
This drug has fifty-six patent family members in twenty-five countries.
The generic ingredient in QALSODY is tofersen. One supplier is listed for this compound. Additional details are available on the tofersen profile page.
DrugPatentWatch® Generic Entry Outlook for Qalsody
Qalsody will be eligible for patent challenges on April 25, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 25, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for QALSODY
International Patents: | 56 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for QALSODY |
What excipients (inactive ingredients) are in QALSODY? | QALSODY excipients list |
DailyMed Link: | QALSODY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for QALSODY
Generic Entry Date for QALSODY*:
Constraining patent/regulatory exclusivity:
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE NDA:
Dosage:
SOLUTION;INTRATHECAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for QALSODY
US Patents and Regulatory Information for QALSODY
QALSODY is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of QALSODY is ⤷ Try a Trial.
This potential generic entry date is based on TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting QALSODY
Compositions for modulating SOD-1 expression
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Compositions for modulating SOD-1 expression
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
Compositions for modulating SOD-1 expression
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
FDA Regulatory Exclusivity protecting QALSODY
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
Exclusivity Expiration: ⤷ Try a Trial
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QALSODY
See the table below for patents covering QALSODY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Singapore | 11201608109T | COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION | ⤷ Try a Trial |
Malaysia | 192634 | COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2015153800 | ⤷ Try a Trial | |
Denmark | 3126499 | ⤷ Try a Trial | |
Japan | 2023027299 | SOD-1発現を調節するための組成物 | ⤷ Try a Trial |
Serbia | 63487 | KOMPOZICIJE ZA MODULACIJU EKSPRESIJE SOD-1 (COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |